Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) announced a strategic refocusing of its research and development portfolio following the expiration and termination of its option and license arrangements with PinCell S.r.l. for the PC111 program on August 31. The company clarified that the decision was not based on any new negative scientific findings regarding PC111 but rather was a deliberate move to concentrate R&D resources on its proprietary NanoAb platform while preserving capital and management capacity for its contract development and manufacturing organization (CDMO) business.
The refocusing comes as Scinai advances two IL-17 programs within its NanoAb platform, including an intradermal psoriasis program that is under evaluation for approximately €12 million in grant financing in Poland. This potential non-dilutive funding would support the program's progression, underscoring the company's commitment to its core immunology pipeline.
In parallel, the company reported approximately $3.1 million in committed CDMO customer orders as of August 16, reflecting the strength of its service business. Scinai continues to pursue approximately $5 million in CDMO revenue for 2026, subject to project execution, timing, revenue recognition, and additional business opportunities. This revenue-generating arm provides a financial foundation that supports the company's R&D efforts.
The strategic shift is pivotal for Scinai as it aims to maximize value from its NanoAb platform, which is based on technology licensed from the Max Planck Society. By focusing on this platform, the company can leverage its unique capabilities in developing innovative immunology therapies. The decision to step back from the PC111 program, despite its potential, reflects a disciplined approach to resource allocation in a challenging biotech funding environment.
According to the company's announcement, the termination of the PinCell agreement was a planned event, and the decision to not extend it was made after careful evaluation of strategic priorities. Scinai's management believes that concentrating on its NanoAb programs and expanding its CDMO services will generate more significant long-term value for shareholders.
The CDMO business, operated through Scinai Biopharma Services Ltd., provides development and manufacturing services to biotech and pharmaceutical companies from facilities in Jerusalem and Yavne, Israel. This segment not only generates revenue but also offers operational synergies and capabilities that could accelerate the development of Scinai's own pipeline.
Investors are watching how this refocusing will impact Scinai's financial trajectory. The company's ability to secure grant funding for its psoriasis program and grow its CDMO order book will be critical near-term milestones. As of the latest update, the company is actively pursuing these opportunities, and the market will be eager to see execution in the coming quarters.
Scinai's newsroom provides updates on the company's progress at https://ibn.fm/SCNI. For the full press release, visit https://ibn.fm/nnx0Z.
